 Uwe Christians
Concepts (1132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 863 | 11.860 |
Why?
| | Sirolimus | 60 | 2025 | 270 | 6.880 |
Why?
| | Cyclosporine | 74 | 2019 | 268 | 6.410 |
Why?
| | Tandem Mass Spectrometry | 38 | 2025 | 543 | 5.340 |
Why?
| | Tacrolimus | 46 | 2019 | 195 | 4.320 |
Why?
| | Chromatography, High Pressure Liquid | 68 | 2024 | 580 | 4.290 |
Why?
| | Drug Monitoring | 23 | 2020 | 209 | 3.650 |
Why?
| | Kidney Transplantation | 46 | 2018 | 701 | 3.070 |
Why?
| | Chromatography, Liquid | 26 | 2024 | 441 | 2.530 |
Why?
| | Mycophenolic Acid | 15 | 2017 | 117 | 2.350 |
Why?
| | Metabolomics | 18 | 2022 | 686 | 2.270 |
Why?
| | Kidney | 25 | 2022 | 1475 | 2.200 |
Why?
| | Microsomes, Liver | 19 | 2019 | 81 | 2.070 |
Why?
| | Everolimus | 25 | 2020 | 88 | 2.030 |
Why?
| | Mass Spectrometry | 34 | 2021 | 739 | 1.810 |
Why?
| | Biomarkers | 28 | 2025 | 4111 | 1.680 |
Why?
| | Dronabinol | 16 | 2025 | 234 | 1.610 |
Why?
| | Graft Rejection | 26 | 2019 | 577 | 1.390 |
Why?
| | Liver Transplantation | 28 | 2018 | 842 | 1.310 |
Why?
| | Proteomics | 18 | 2024 | 1109 | 1.270 |
Why?
| | Cannabinoids | 9 | 2025 | 167 | 1.210 |
Why?
| | Cannabidiol | 7 | 2025 | 124 | 1.190 |
Why?
| | Plant Extracts | 6 | 2024 | 209 | 1.110 |
Why?
| | Cannabis | 12 | 2024 | 495 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 39 | 1.060 |
Why?
| | Oxidative Stress | 17 | 2019 | 1322 | 1.050 |
Why?
| | Cytochrome P-450 CYP3A | 20 | 2021 | 88 | 1.040 |
Why?
| | Rats | 62 | 2024 | 5564 | 1.020 |
Why?
| | Organ Transplantation | 10 | 2019 | 250 | 1.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2017 | 442 | 1.000 |
Why?
| | Hallucinogens | 6 | 2024 | 106 | 1.000 |
Why?
| | Humans | 240 | 2025 | 138102 | 1.000 |
Why?
| | Pravastatin | 9 | 2021 | 41 | 0.970 |
Why?
| | Dried Blood Spot Testing | 3 | 2020 | 119 | 0.970 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 180 | 0.940 |
Why?
| | Hydrocortisone | 3 | 2025 | 310 | 0.930 |
Why?
| | Drug Interactions | 27 | 2025 | 406 | 0.930 |
Why?
| | Reproducibility of Results | 27 | 2025 | 3301 | 0.920 |
Why?
| | Cytochrome P-450 Enzyme System | 17 | 2019 | 156 | 0.900 |
Why?
| | Immunoassay | 3 | 2020 | 113 | 0.900 |
Why?
| | Metabolome | 5 | 2022 | 351 | 0.860 |
Why?
| | Animals | 120 | 2025 | 37151 | 0.830 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 262 | 0.820 |
Why?
| | Proteome | 5 | 2017 | 471 | 0.810 |
Why?
| | Mitochondria | 6 | 2017 | 951 | 0.810 |
Why?
| | Factor Xa Inhibitors | 2 | 2025 | 172 | 0.800 |
Why?
| | Drugs, Generic | 4 | 2019 | 23 | 0.790 |
Why?
| | Lovastatin | 7 | 2013 | 38 | 0.790 |
Why?
| | Intestinal Mucosa | 7 | 2017 | 621 | 0.760 |
Why?
| | Male | 140 | 2025 | 67984 | 0.750 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 451 | 0.750 |
Why?
| | Nucleotides | 2 | 2017 | 126 | 0.750 |
Why?
| | Isoprostanes | 4 | 2012 | 15 | 0.730 |
Why?
| | Biological Availability | 12 | 2019 | 134 | 0.730 |
Why?
| | Magnetic Resonance Spectroscopy | 18 | 2017 | 616 | 0.730 |
Why?
| | Pharmaceutical Preparations | 3 | 2017 | 177 | 0.730 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 200 | 0.720 |
Why?
| | Cortisone | 1 | 2021 | 10 | 0.720 |
Why?
| | Female | 116 | 2025 | 73648 | 0.700 |
Why?
| | Pregnanolone | 1 | 2021 | 37 | 0.690 |
Why?
| | TOR Serine-Threonine Kinases | 7 | 2016 | 414 | 0.690 |
Why?
| | Cyclosporins | 18 | 2001 | 70 | 0.690 |
Why?
| | Endocannabinoids | 5 | 2025 | 64 | 0.680 |
Why?
| | Urine | 2 | 2017 | 59 | 0.670 |
Why?
| | Transplant Recipients | 4 | 2019 | 186 | 0.660 |
Why?
| | Drug-Eluting Stents | 7 | 2025 | 82 | 0.660 |
Why?
| | Estrogen Receptor beta | 2 | 2012 | 40 | 0.660 |
Why?
| | Energy Metabolism | 17 | 2022 | 923 | 0.650 |
Why?
| | Dinoprost | 6 | 2019 | 44 | 0.650 |
Why?
| | Hemorrhage | 2 | 2025 | 719 | 0.640 |
Why?
| | Progesterone | 1 | 2021 | 256 | 0.630 |
Why?
| | Dose-Response Relationship, Drug | 25 | 2024 | 2022 | 0.630 |
Why?
| | Therapeutic Equivalency | 6 | 2019 | 30 | 0.630 |
Why?
| | Limit of Detection | 11 | 2024 | 87 | 0.620 |
Why?
| | Pharmacology | 1 | 2019 | 10 | 0.610 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 48 | 0.610 |
Why?
| | Tissue Distribution | 12 | 2019 | 320 | 0.600 |
Why?
| | Signal Transduction | 11 | 2017 | 5068 | 0.590 |
Why?
| | Brain | 13 | 2019 | 2725 | 0.580 |
Why?
| | Models, Biological | 9 | 2021 | 1784 | 0.570 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.550 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 31 | 0.540 |
Why?
| | Intestine, Small | 5 | 2006 | 155 | 0.530 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 29 | 0.530 |
Why?
| | Toxicity Tests | 1 | 2017 | 40 | 0.530 |
Why?
| | Menopause | 3 | 2019 | 326 | 0.530 |
Why?
| | Cardiovascular Agents | 5 | 2025 | 155 | 0.530 |
Why?
| | Rats, Wistar | 16 | 2024 | 448 | 0.530 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2024 | 611 | 0.530 |
Why?
| | Anticoagulants | 2 | 2020 | 659 | 0.510 |
Why?
| | Myocardium | 4 | 2017 | 900 | 0.510 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.490 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.490 |
Why?
| | Choline | 3 | 2022 | 131 | 0.480 |
Why?
| | Marijuana Smoking | 4 | 2025 | 254 | 0.480 |
Why?
| | Lipid Metabolism | 2 | 2017 | 523 | 0.480 |
Why?
| | Kidney Diseases | 3 | 2018 | 409 | 0.470 |
Why?
| | Fishes | 1 | 2016 | 110 | 0.460 |
Why?
| | Substance Abuse Detection | 4 | 2025 | 92 | 0.460 |
Why?
| | Analgesics, Opioid | 8 | 2021 | 1049 | 0.460 |
Why?
| | Clinical Laboratory Techniques | 1 | 2015 | 94 | 0.450 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 322 | 0.450 |
Why?
| | Oxidoreductases, N-Demethylating | 6 | 2004 | 16 | 0.450 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 202 | 0.440 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1946 | 0.430 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.430 |
Why?
| | Amino Acids | 3 | 2016 | 499 | 0.430 |
Why?
| | Premature Birth | 3 | 2025 | 340 | 0.430 |
Why?
| | Adult | 62 | 2025 | 38063 | 0.430 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 165 | 0.420 |
Why?
| | Polyenes | 8 | 1998 | 16 | 0.420 |
Why?
| | Hydroxyurea | 1 | 2013 | 35 | 0.410 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 38 | 0.410 |
Why?
| | Molecular Structure | 10 | 2014 | 495 | 0.410 |
Why?
| | Metabolic Clearance Rate | 9 | 2019 | 107 | 0.410 |
Why?
| | Protein Kinases | 4 | 2017 | 308 | 0.410 |
Why?
| | Anticholesteremic Agents | 4 | 2007 | 154 | 0.400 |
Why?
| | Piperazines | 4 | 2009 | 345 | 0.400 |
Why?
| | Coated Materials, Biocompatible | 3 | 2020 | 64 | 0.390 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 91 | 0.390 |
Why?
| | Pyrimidines | 4 | 2014 | 467 | 0.390 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 37 | 0.380 |
Why?
| | Heart Transplantation | 8 | 2017 | 694 | 0.380 |
Why?
| | Drug Therapy, Combination | 18 | 2025 | 1034 | 0.380 |
Why?
| | Middle Aged | 49 | 2025 | 33509 | 0.380 |
Why?
| | Administration, Oral | 12 | 2025 | 786 | 0.380 |
Why?
| | Liver | 14 | 2023 | 1874 | 0.380 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2012 | 32 | 0.380 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 854 | 0.380 |
Why?
| | In Vitro Techniques | 18 | 2017 | 1088 | 0.370 |
Why?
| | Vasomotor System | 1 | 2012 | 46 | 0.370 |
Why?
| | Hypoxia | 6 | 2024 | 1121 | 0.360 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2125 | 0.360 |
Why?
| | Macrophages, Alveolar | 4 | 2016 | 396 | 0.360 |
Why?
| | Lung Transplantation | 8 | 2000 | 314 | 0.350 |
Why?
| | Area Under Curve | 9 | 2021 | 306 | 0.340 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2021 | 24 | 0.340 |
Why?
| | Swine | 15 | 2017 | 796 | 0.340 |
Why?
| | Artifacts | 1 | 2011 | 129 | 0.340 |
Why?
| | Microsomes | 5 | 1998 | 33 | 0.340 |
Why?
| | Young Adult | 25 | 2025 | 13329 | 0.340 |
Why?
| | Acetaminophen | 1 | 2013 | 265 | 0.330 |
Why?
| | Hydroxylation | 5 | 2019 | 42 | 0.330 |
Why?
| | Prospective Studies | 18 | 2025 | 7603 | 0.320 |
Why?
| | Double-Blind Method | 11 | 2025 | 1922 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 18 | 2023 | 2472 | 0.320 |
Why?
| | Calcineurin Inhibitors | 6 | 2014 | 73 | 0.320 |
Why?
| | Graft Survival | 6 | 2018 | 526 | 0.310 |
Why?
| | Phosphates | 5 | 2012 | 180 | 0.310 |
Why?
| | Drug Approval | 1 | 2010 | 87 | 0.310 |
Why?
| | Isoniazid | 2 | 2006 | 62 | 0.310 |
Why?
| | Lidocaine | 2 | 2023 | 40 | 0.310 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4309 | 0.310 |
Why?
| | Cell Proliferation | 10 | 2020 | 2472 | 0.310 |
Why?
| | Bile | 7 | 1992 | 25 | 0.300 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 934 | 0.300 |
Why?
| | Pain, Postoperative | 3 | 2018 | 281 | 0.300 |
Why?
| | Theophylline | 2 | 2020 | 40 | 0.300 |
Why?
| | Diltiazem | 3 | 1997 | 19 | 0.300 |
Why?
| | Time Factors | 19 | 2025 | 6845 | 0.300 |
Why?
| | Glucose | 7 | 2017 | 1033 | 0.290 |
Why?
| | Flavanones | 1 | 2008 | 7 | 0.290 |
Why?
| | Cross-Over Studies | 6 | 2025 | 550 | 0.290 |
Why?
| | Drugs, Chinese Herbal | 1 | 2008 | 21 | 0.290 |
Why?
| | Pregnancy | 13 | 2025 | 6789 | 0.290 |
Why?
| | Paclitaxel | 3 | 2020 | 237 | 0.290 |
Why?
| | Medical Marijuana | 2 | 2021 | 121 | 0.290 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 69 | 0.290 |
Why?
| | Adolescent | 30 | 2025 | 21637 | 0.290 |
Why?
| | Child | 25 | 2022 | 21990 | 0.280 |
Why?
| | Neurons | 3 | 2019 | 1593 | 0.280 |
Why?
| | Liver Function Tests | 5 | 2025 | 106 | 0.280 |
Why?
| | Biotransformation | 18 | 2021 | 62 | 0.270 |
Why?
| | Calcium Channel Blockers | 3 | 1997 | 166 | 0.270 |
Why?
| | Buprenorphine | 2 | 2021 | 176 | 0.270 |
Why?
| | Naltrexone | 1 | 2008 | 97 | 0.270 |
Why?
| | Angioplasty, Balloon | 3 | 2020 | 93 | 0.260 |
Why?
| | Drug Stability | 4 | 2013 | 161 | 0.260 |
Why?
| | Pyridostigmine Bromide | 1 | 2006 | 5 | 0.260 |
Why?
| | Lipase | 2 | 2020 | 69 | 0.260 |
Why?
| | Half-Life | 8 | 2019 | 145 | 0.260 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 33 | 0.250 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 45 | 0.250 |
Why?
| | Tachycardia | 1 | 2006 | 56 | 0.250 |
Why?
| | Coronary Artery Disease | 3 | 2025 | 701 | 0.250 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 1804 | 0.250 |
Why?
| | Glomerular Filtration Rate | 8 | 2022 | 746 | 0.250 |
Why?
| | Reactive Oxygen Species | 4 | 2010 | 626 | 0.250 |
Why?
| | Macaca fascicularis | 13 | 2008 | 68 | 0.250 |
Why?
| | Fibrinolytic Agents | 2 | 2025 | 274 | 0.250 |
Why?
| | Drug Carriers | 2 | 2020 | 126 | 0.240 |
Why?
| | Regression Analysis | 5 | 2020 | 1012 | 0.240 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 46 | 0.240 |
Why?
| | Dogs | 6 | 2025 | 405 | 0.240 |
Why?
| | Mice | 19 | 2025 | 17769 | 0.240 |
Why?
| | Drug Delivery Systems | 4 | 2020 | 357 | 0.240 |
Why?
| | Pipecolic Acids | 1 | 2025 | 25 | 0.240 |
Why?
| | Mice, Knockout | 6 | 2019 | 3014 | 0.240 |
Why?
| | Coronary Thrombosis | 1 | 2025 | 24 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 335 | 0.240 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3404 | 0.240 |
Why?
| | Depression | 3 | 2025 | 1462 | 0.240 |
Why?
| | Isomerism | 2 | 2024 | 55 | 0.230 |
Why?
| | Heptanoic Acids | 2 | 2007 | 66 | 0.230 |
Why?
| | Corticosterone | 2 | 2024 | 239 | 0.230 |
Why?
| | Wound Infection | 1 | 2025 | 33 | 0.230 |
Why?
| | Caffeine | 1 | 2025 | 67 | 0.230 |
Why?
| | Catheters | 2 | 2017 | 72 | 0.230 |
Why?
| | Drug Synergism | 7 | 2014 | 369 | 0.230 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 72 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Cholic Acid | 1 | 2024 | 4 | 0.230 |
Why?
| | Oxylipins | 1 | 2025 | 41 | 0.230 |
Why?
| | Inflammation | 9 | 2025 | 2847 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 7 | 0.230 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 397 | 0.230 |
Why?
| | Alkaloids | 1 | 2024 | 32 | 0.220 |
Why?
| | Infant, Newborn | 12 | 2024 | 6140 | 0.220 |
Why?
| | Ketorolac | 2 | 2017 | 23 | 0.220 |
Why?
| | Clemastine | 1 | 2024 | 1 | 0.220 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 847 | 0.220 |
Why?
| | Benzylidene Compounds | 2 | 2017 | 20 | 0.220 |
Why?
| | Diphosphonates | 1 | 2025 | 67 | 0.220 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Animals, Newborn | 3 | 2024 | 847 | 0.220 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 119 | 0.220 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 84 | 0.220 |
Why?
| | Pyrroles | 2 | 2007 | 212 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 28 | 0.220 |
Why?
| | Cholesterol | 5 | 2013 | 411 | 0.210 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1755 | 0.210 |
Why?
| | Mice, Inbred C57BL | 10 | 2024 | 5769 | 0.210 |
Why?
| | Kinetics | 8 | 2013 | 1640 | 0.210 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 47 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 22 | 0.210 |
Why?
| | Protease Inhibitors | 1 | 2004 | 109 | 0.210 |
Why?
| | Gestational Age | 3 | 2022 | 915 | 0.210 |
Why?
| | Cell Line | 7 | 2017 | 2865 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 511 | 0.210 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 164 | 0.210 |
Why?
| | Morphine | 2 | 2018 | 161 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 239 | 0.210 |
Why?
| | Niacinamide | 1 | 2024 | 82 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 64 | 0.210 |
Why?
| | Deoxycytidine | 1 | 2025 | 192 | 0.210 |
Why?
| | Leukemia | 2 | 2020 | 241 | 0.210 |
Why?
| | Anti-HIV Agents | 3 | 2013 | 836 | 0.200 |
Why?
| | Child, Preschool | 12 | 2024 | 11142 | 0.200 |
Why?
| | Macrolides | 1 | 2003 | 67 | 0.200 |
Why?
| | Rivaroxaban | 1 | 2025 | 255 | 0.200 |
Why?
| | Mixed Function Oxygenases | 5 | 2001 | 46 | 0.200 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 533 | 0.200 |
Why?
| | Adiponectin | 1 | 2025 | 243 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 96 | 0.200 |
Why?
| | Transplantation | 4 | 2016 | 35 | 0.200 |
Why?
| | Glycolysis | 4 | 2012 | 321 | 0.200 |
Why?
| | Neurofibromatosis 1 | 2 | 2015 | 56 | 0.200 |
Why?
| | Blood Transfusion | 1 | 2025 | 337 | 0.190 |
Why?
| | Psychomotor Performance | 1 | 2025 | 312 | 0.190 |
Why?
| | Blotting, Western | 8 | 2012 | 1223 | 0.190 |
Why?
| | Rats, Inbred Lew | 11 | 2012 | 113 | 0.190 |
Why?
| | White Matter | 1 | 2024 | 143 | 0.190 |
Why?
| | Glutamine | 3 | 2012 | 104 | 0.190 |
Why?
| | Hepatitis C | 1 | 2005 | 274 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 559 | 0.190 |
Why?
| | Pharmacogenetics | 3 | 2010 | 165 | 0.190 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 91 | 0.190 |
Why?
| | Kidney Failure, Chronic | 4 | 2017 | 572 | 0.180 |
Why?
| | Heart Rate, Fetal | 1 | 2021 | 22 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 10 | 0.180 |
Why?
| | Homocysteine | 2 | 2019 | 159 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 491 | 0.180 |
Why?
| | Hepatectomy | 2 | 2023 | 235 | 0.180 |
Why?
| | Prostaglandins | 2 | 2019 | 101 | 0.180 |
Why?
| | Kynurenine | 2 | 2022 | 114 | 0.180 |
Why?
| | Biological Transport, Active | 5 | 2006 | 69 | 0.180 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 85 | 0.180 |
Why?
| | Transplantation, Heterologous | 3 | 2006 | 195 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 178 | 0.180 |
Why?
| | Arginine | 2 | 2025 | 260 | 0.170 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2020 | 38 | 0.170 |
Why?
| | Pilot Projects | 8 | 2023 | 1751 | 0.170 |
Why?
| | Fetal Development | 2 | 2021 | 297 | 0.170 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 121 | 0.170 |
Why?
| | Pain | 2 | 2025 | 761 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2018 | 412 | 0.170 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 112 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 152 | 0.170 |
Why?
| | Anesthetics, Intravenous | 2 | 2016 | 48 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2018 | 194 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2023 | 224 | 0.170 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 10 | 0.170 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 840 | 0.170 |
Why?
| | Pyridines | 2 | 2017 | 498 | 0.170 |
Why?
| | Microspheres | 2 | 2020 | 134 | 0.170 |
Why?
| | Avoidance Learning | 2 | 2024 | 74 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.170 |
Why?
| | Coronary Restenosis | 2 | 2010 | 20 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 324 | 0.170 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 399 | 0.170 |
Why?
| | Keratosis | 1 | 2020 | 16 | 0.170 |
Why?
| | Infant | 11 | 2024 | 9566 | 0.170 |
Why?
| | Glutamic Acid | 2 | 2018 | 248 | 0.170 |
Why?
| | Treatment Outcome | 12 | 2025 | 10832 | 0.160 |
Why?
| | Aged | 18 | 2025 | 23995 | 0.160 |
Why?
| | Lactones | 1 | 2000 | 56 | 0.160 |
Why?
| | Losartan | 1 | 2000 | 14 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 484 | 0.160 |
Why?
| | Tetrazoles | 1 | 2000 | 43 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 407 | 0.160 |
Why?
| | Amygdala | 3 | 2024 | 188 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 55 | 0.160 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 122 | 0.160 |
Why?
| | Reference Standards | 5 | 2016 | 184 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 156 | 0.160 |
Why?
| | Adenosine | 4 | 2017 | 222 | 0.160 |
Why?
| | Opiate Substitution Treatment | 1 | 2021 | 155 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 66 | 0.160 |
Why?
| | Mental Disorders | 2 | 2021 | 1093 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 115 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 97 | 0.160 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 110 | 0.160 |
Why?
| | Carotid Arteries | 2 | 2018 | 209 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 84 | 0.160 |
Why?
| | Postoperative Complications | 5 | 2018 | 2671 | 0.150 |
Why?
| | Astrocytes | 4 | 2011 | 211 | 0.150 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2274 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2025 | 3569 | 0.150 |
Why?
| | Age Factors | 7 | 2018 | 3285 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
| | Perfusion | 6 | 2017 | 223 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 87 | 0.150 |
Why?
| | Fentanyl | 2 | 2011 | 100 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 36 | 0.150 |
Why?
| | Spine | 1 | 2021 | 175 | 0.150 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 98 | 0.150 |
Why?
| | Vascular Diseases | 2 | 2019 | 244 | 0.150 |
Why?
| | Bilirubin | 3 | 1995 | 89 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 21 | 0.150 |
Why?
| | Taurine | 1 | 2019 | 43 | 0.150 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 71 | 0.150 |
Why?
| | Imidazoles | 1 | 2000 | 236 | 0.150 |
Why?
| | Caspase 3 | 2 | 2017 | 249 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 102 | 0.150 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 184 | 0.150 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 24 | 0.140 |
Why?
| | Legislation, Drug | 1 | 1999 | 82 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2025 | 758 | 0.140 |
Why?
| | Systems Biology | 1 | 2019 | 69 | 0.140 |
Why?
| | Homocystinuria | 1 | 2019 | 71 | 0.140 |
Why?
| | Naphthalenes | 1 | 1998 | 60 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 329 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 215 | 0.140 |
Why?
| | Creatinine | 5 | 2022 | 487 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 45 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 422 | 0.140 |
Why?
| | Iohexol | 1 | 2018 | 22 | 0.140 |
Why?
| | Excipients | 1 | 2018 | 54 | 0.140 |
Why?
| | Vascular Access Devices | 1 | 2018 | 26 | 0.140 |
Why?
| | Reference Values | 4 | 2013 | 803 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 36 | 0.140 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 27 | 0.140 |
Why?
| | Phospholipids | 5 | 2013 | 219 | 0.140 |
Why?
| | Genotype | 5 | 2019 | 1876 | 0.140 |
Why?
| | Enzyme Activation | 2 | 2017 | 818 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 21 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 203 | 0.140 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.140 |
Why?
| | Cells, Cultured | 10 | 2017 | 4160 | 0.140 |
Why?
| | Endothelins | 1 | 2017 | 63 | 0.140 |
Why?
| | Sex Factors | 3 | 2019 | 2071 | 0.130 |
Why?
| | Acute Kidney Injury | 2 | 2018 | 803 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 57 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.130 |
Why?
| | Enzyme Stability | 1 | 2017 | 73 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 905 | 0.130 |
Why?
| | Guanosine | 1 | 2017 | 41 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 125 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2019 | 190 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2017 | 191 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 283 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 149 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 168 | 0.130 |
Why?
| | Glutathione | 4 | 2009 | 357 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.130 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 210 | 0.130 |
Why?
| | Plasma | 2 | 2017 | 217 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 289 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2021 | 530 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 70 | 0.130 |
Why?
| | Ischemia | 2 | 2012 | 408 | 0.130 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Necrosis | 1 | 2017 | 247 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1157 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2016 | 643 | 0.120 |
Why?
| | Vitamin D | 1 | 2019 | 398 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 317 | 0.120 |
Why?
| | Laboratory Proficiency Testing | 1 | 2015 | 8 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 1996 | 288 | 0.120 |
Why?
| | Gastrectomy | 1 | 2017 | 131 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2007 | 135 | 0.120 |
Why?
| | Tunica Intima | 2 | 2010 | 83 | 0.120 |
Why?
| | Mutation | 2 | 2022 | 3994 | 0.120 |
Why?
| | Propofol | 1 | 2016 | 74 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 259 | 0.120 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 75 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 277 | 0.120 |
Why?
| | Hepatocytes | 2 | 2006 | 217 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 200 | 0.120 |
Why?
| | Cerebral Cortex | 2 | 2024 | 434 | 0.120 |
Why?
| | Sex Characteristics | 3 | 2023 | 770 | 0.120 |
Why?
| | Sulfonamides | 2 | 2025 | 510 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 178 | 0.110 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.110 |
Why?
| | Cholestasis | 3 | 1995 | 209 | 0.110 |
Why?
| | Larva | 1 | 2016 | 235 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 351 | 0.110 |
Why?
| | HIV Infections | 3 | 2019 | 2945 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 109 | 0.110 |
Why?
| | Extinction, Psychological | 1 | 2015 | 86 | 0.110 |
Why?
| | Benzamides | 3 | 2009 | 209 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1060 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 208 | 0.110 |
Why?
| | Pharmacokinetics | 3 | 2020 | 27 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 433 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 88 | 0.110 |
Why?
| | C-Reactive Protein | 3 | 2022 | 415 | 0.110 |
Why?
| | Rabbits | 3 | 2017 | 765 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1702 | 0.110 |
Why?
| | Specimen Handling | 1 | 2015 | 183 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | United States | 5 | 2020 | 15028 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 641 | 0.110 |
Why?
| | Carbon Isotopes | 2 | 2024 | 145 | 0.110 |
Why?
| | Prognosis | 4 | 2018 | 3982 | 0.110 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2006 | 196 | 0.100 |
Why?
| | Altitude Sickness | 2 | 2006 | 148 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 23 | 0.100 |
Why?
| | Mental Recall | 1 | 2015 | 205 | 0.100 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 34 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 40 | 0.100 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 43 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 271 | 0.100 |
Why?
| | Drug Resistance, Multiple | 3 | 2002 | 23 | 0.100 |
Why?
| | Apoptosis | 4 | 2017 | 2555 | 0.100 |
Why?
| | Fatty Acids | 2 | 2014 | 446 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 106 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Brachial Artery | 3 | 2019 | 212 | 0.100 |
Why?
| | Adenosine Triphosphate | 4 | 2004 | 487 | 0.100 |
Why?
| | Schizophrenia | 1 | 2017 | 446 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1214 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 56 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1859 | 0.100 |
Why?
| | Calibration | 4 | 2019 | 146 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 76 | 0.100 |
Why?
| | Iron | 2 | 2010 | 324 | 0.100 |
Why?
| | Graft vs Host Disease | 2 | 2000 | 252 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2012 | 57 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 538 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 786 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Models, Theoretical | 3 | 2025 | 583 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 97 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 18 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 132 | 0.090 |
Why?
| | Monitoring, Physiologic | 3 | 2012 | 270 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2020 | 15750 | 0.090 |
Why?
| | Swine, Miniature | 2 | 2010 | 88 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 618 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 218 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Association Learning | 1 | 2012 | 63 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 60 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 279 | 0.090 |
Why?
| | Down Syndrome | 1 | 2018 | 486 | 0.090 |
Why?
| | Vagus Nerve | 1 | 2012 | 87 | 0.090 |
Why?
| | Hot Flashes | 1 | 2012 | 87 | 0.090 |
Why?
| | Ritonavir | 1 | 2011 | 75 | 0.090 |
Why?
| | Lung | 9 | 2013 | 4065 | 0.090 |
Why?
| | Morphine Derivatives | 1 | 2011 | 17 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 163 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 557 | 0.090 |
Why?
| | Disease Progression | 4 | 2022 | 2730 | 0.090 |
Why?
| | Consumer Product Safety | 1 | 2011 | 33 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2013 | 340 | 0.090 |
Why?
| | Cell Cycle | 2 | 2011 | 600 | 0.090 |
Why?
| | Survival Analysis | 2 | 2012 | 1292 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 257 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 861 | 0.090 |
Why?
| | Internet | 1 | 2015 | 681 | 0.090 |
Why?
| | Methylation | 1 | 2011 | 228 | 0.080 |
Why?
| | Tachyphylaxis | 1 | 2010 | 5 | 0.080 |
Why?
| | Cholinergic Agents | 1 | 2010 | 18 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 753 | 0.080 |
Why?
| | Structure-Activity Relationship | 5 | 2013 | 568 | 0.080 |
Why?
| | Verapamil | 2 | 2009 | 37 | 0.080 |
Why?
| | Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 2 | 2017 | 39 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3158 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 22 | 0.080 |
Why?
| | Needs Assessment | 1 | 2012 | 381 | 0.080 |
Why?
| | Sensation | 1 | 2010 | 53 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 162 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 64 | 0.080 |
Why?
| | Tablets, Enteric-Coated | 2 | 2007 | 5 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 301 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2014 | 639 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 492 | 0.080 |
Why?
| | Micromonosporaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Albuminuria | 1 | 2010 | 187 | 0.080 |
Why?
| | Conditioning, Classical | 2 | 2024 | 104 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 98 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 189 | 0.080 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.080 |
Why?
| | Diclofenac | 1 | 2009 | 15 | 0.080 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 323 | 0.080 |
Why?
| | Neoplasms | 2 | 2016 | 2712 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 461 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 373 | 0.080 |
Why?
| | Risk Factors | 5 | 2025 | 10433 | 0.080 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 22 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2021 | 153 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 11 | 0.080 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2012 | 193 | 0.080 |
Why?
| | Loperamide | 1 | 2009 | 11 | 0.080 |
Why?
| | Radioimmunoassay | 6 | 1996 | 169 | 0.080 |
Why?
| | Surface Properties | 3 | 2019 | 411 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 130 | 0.080 |
Why?
| | Creatine | 2 | 2006 | 59 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
| | Aorta | 2 | 2003 | 417 | 0.070 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 346 | 0.070 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2006 | 64 | 0.070 |
Why?
| | Species Specificity | 2 | 2008 | 584 | 0.070 |
Why?
| | Drug Evaluation | 2 | 2000 | 83 | 0.070 |
Why?
| | Kidney Medulla | 1 | 2008 | 33 | 0.070 |
Why?
| | Lymphocyte Activation | 6 | 2003 | 1146 | 0.070 |
Why?
| | Automation | 2 | 2016 | 95 | 0.070 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 29 | 0.070 |
Why?
| | Guinea Pigs | 1 | 2008 | 170 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2025 | 971 | 0.070 |
Why?
| | Hydroxybutyrates | 2 | 2005 | 14 | 0.070 |
Why?
| | Taste | 2 | 2024 | 230 | 0.070 |
Why?
| | Cytokines | 4 | 2025 | 2079 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 257 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 142 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Rats, Inbred F344 | 1 | 2008 | 267 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1075 | 0.070 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 173 | 0.070 |
Why?
| | Enzymes | 1 | 2008 | 65 | 0.070 |
Why?
| | Drug Combinations | 3 | 2024 | 341 | 0.070 |
Why?
| | Switzerland | 1 | 2007 | 38 | 0.070 |
Why?
| | Macaca mulatta | 1 | 2008 | 186 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 344 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 396 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2011 | 124 | 0.070 |
Why?
| | Emulsions | 5 | 2016 | 55 | 0.070 |
Why?
| | Myocardial Infarction | 2 | 2007 | 1053 | 0.070 |
Why?
| | Nanoparticles | 1 | 2013 | 468 | 0.070 |
Why?
| | Acute Disease | 6 | 2005 | 1004 | 0.070 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.070 |
Why?
| | Prosthesis Design | 2 | 2025 | 330 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 274 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2013 | 120 | 0.070 |
Why?
| | NAD | 2 | 2004 | 77 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2145 | 0.070 |
Why?
| | Serum Albumin | 3 | 2019 | 150 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 68 | 0.070 |
Why?
| | Cardiotonic Agents | 1 | 2007 | 92 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 181 | 0.060 |
Why?
| | Caco-2 Cells | 3 | 2003 | 76 | 0.060 |
Why?
| | Immune Tolerance | 3 | 2017 | 366 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5144 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1100 | 0.060 |
Why?
| | Fetus | 2 | 2021 | 801 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 45 | 0.060 |
Why?
| | Nitric Oxide | 3 | 2017 | 895 | 0.060 |
Why?
| | Lactic Acid | 4 | 2009 | 308 | 0.060 |
Why?
| | Liver Diseases | 2 | 2024 | 301 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 568 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 408 | 0.060 |
Why?
| | Macaca | 1 | 2006 | 63 | 0.060 |
Why?
| | Food-Drug Interactions | 1 | 2005 | 11 | 0.060 |
Why?
| | Body Weight | 5 | 2001 | 990 | 0.060 |
Why?
| | Growth Inhibitors | 1 | 2005 | 44 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2005 | 30 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2077 | 0.060 |
Why?
| | Lactates | 1 | 2005 | 84 | 0.060 |
Why?
| | Methylamines | 1 | 2005 | 34 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 377 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 103 | 0.060 |
Why?
| | Ships | 1 | 1985 | 5 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 48 | 0.060 |
Why?
| | Phosphorylation | 5 | 2012 | 1760 | 0.060 |
Why?
| | Posture | 1 | 2006 | 191 | 0.060 |
Why?
| | Organ Size | 3 | 2015 | 473 | 0.060 |
Why?
| | Iliac Artery | 2 | 2017 | 54 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 99 | 0.060 |
Why?
| | Streptozocin | 1 | 2005 | 22 | 0.060 |
Why?
| | CD55 Antigens | 1 | 2005 | 29 | 0.060 |
Why?
| | Hair | 1 | 2025 | 94 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 645 | 0.060 |
Why?
| | Hot Temperature | 2 | 2012 | 394 | 0.060 |
Why?
| | Triglycerides | 3 | 2011 | 528 | 0.060 |
Why?
| | Insulin Infusion Systems | 1 | 2009 | 397 | 0.060 |
Why?
| | Paraplegia | 1 | 1985 | 60 | 0.060 |
Why?
| | Complement Inactivator Proteins | 1 | 2005 | 42 | 0.060 |
Why?
| | Colorado | 5 | 2021 | 4553 | 0.060 |
Why?
| | Hippocampus | 1 | 2010 | 903 | 0.060 |
Why?
| | Warfarin | 1 | 2006 | 154 | 0.060 |
Why?
| | Drug Design | 1 | 2005 | 165 | 0.060 |
Why?
| | Troleandomycin | 3 | 1999 | 3 | 0.060 |
Why?
| | Steroids | 2 | 2005 | 159 | 0.060 |
Why?
| | Saccharin | 1 | 2024 | 6 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 71 | 0.050 |
Why?
| | Consensus | 2 | 2019 | 676 | 0.050 |
Why?
| | Vasodilation | 2 | 2018 | 514 | 0.050 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1108 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2005 | 122 | 0.050 |
Why?
| | Calcineurin | 2 | 2004 | 107 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 27 | 0.050 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 204 | 0.050 |
Why?
| | Stress, Psychological | 2 | 2025 | 1122 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 796 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Trimethylsilyl Compounds | 1 | 2004 | 5 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1890 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 25 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 1059 | 0.050 |
Why?
| | Saliva | 1 | 2025 | 239 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2005 | 204 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1448 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 223 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 91 | 0.050 |
Why?
| | Analysis of Variance | 2 | 1997 | 1311 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3037 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2004 | 194 | 0.050 |
Why?
| | Midazolam | 1 | 2003 | 58 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 149 | 0.050 |
Why?
| | Protein Binding | 3 | 2018 | 2232 | 0.050 |
Why?
| | Insulin | 3 | 2009 | 2405 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 318 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 946 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 204 | 0.050 |
Why?
| | NADP | 2 | 1994 | 54 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 2 | 2018 | 39 | 0.050 |
Why?
| | Pancreas Transplantation | 1 | 2003 | 71 | 0.050 |
Why?
| | Altitude | 3 | 2017 | 469 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2009 | 897 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 417 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5850 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 161 | 0.050 |
Why?
| | Leukocytes | 1 | 2024 | 307 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2000 | 104 | 0.050 |
Why?
| | Ketoconazole | 2 | 1999 | 3 | 0.050 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 343 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2024 | 167 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 32 | 0.050 |
Why?
| | Cognition | 2 | 2023 | 1173 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2024 | 178 | 0.050 |
Why?
| | Sports | 1 | 1985 | 236 | 0.050 |
Why?
| | Oral Mucosal Absorption | 1 | 2021 | 1 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 1 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 42 | 0.050 |
Why?
| | Administration, Sublingual | 1 | 2021 | 12 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 552 | 0.050 |
Why?
| | Wine | 1 | 2001 | 12 | 0.050 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 22 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5556 | 0.050 |
Why?
| | Plant Preparations | 1 | 2002 | 37 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.050 |
Why?
| | Drug Overdose | 1 | 2006 | 354 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 58 | 0.050 |
Why?
| | Biological Transport | 2 | 2003 | 401 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 306 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2002 | 72 | 0.040 |
Why?
| | Cell Survival | 3 | 2012 | 1130 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 119 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 80 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2024 | 506 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 115 | 0.040 |
Why?
| | Glomerular Mesangium | 2 | 1991 | 21 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 838 | 0.040 |
Why?
| | Microchemistry | 3 | 2000 | 19 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 84 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.040 |
Why?
| | Haplotypes | 2 | 2013 | 495 | 0.040 |
Why?
| | Gene Silencing | 2 | 2012 | 197 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 434 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 501 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1718 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2029 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2013 | 360 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 241 | 0.040 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 46 | 0.040 |
Why?
| | Pyrazoles | 1 | 2004 | 421 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
| | LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
| | Antimetabolites | 1 | 2000 | 21 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 141 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 275 | 0.040 |
Why?
| | Reward | 1 | 2022 | 249 | 0.040 |
Why?
| | Logistic Models | 2 | 2022 | 2081 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 470 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.040 |
Why?
| | Risk Assessment | 3 | 2018 | 3471 | 0.040 |
Why?
| | Heart | 1 | 2003 | 611 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 405 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1999 | 18 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2198 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 81 | 0.040 |
Why?
| | Rats, Inbred BN | 4 | 2000 | 56 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 190 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.040 |
Why?
| | Attention | 1 | 2023 | 442 | 0.040 |
Why?
| | Citrus | 1 | 1999 | 8 | 0.040 |
Why?
| | K562 Cells | 2 | 2009 | 93 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 161 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 2001 | 1419 | 0.040 |
Why?
| | Epithelium | 1 | 2000 | 316 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1290 | 0.040 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 196 | 0.040 |
Why?
| | Beverages | 1 | 1999 | 68 | 0.040 |
Why?
| | Maternal Age | 1 | 2019 | 127 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Individuality | 1 | 2000 | 158 | 0.040 |
Why?
| | Antigens, CD | 1 | 2001 | 530 | 0.040 |
Why?
| | Amides | 1 | 1999 | 93 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 211 | 0.040 |
Why?
| | Ultrafiltration | 1 | 2018 | 29 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 168 | 0.040 |
Why?
| | Europe | 1 | 1999 | 404 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 35 | 0.040 |
Why?
| | Sus scrofa | 1 | 2018 | 57 | 0.040 |
Why?
| | F2-Isoprostanes | 2 | 2009 | 21 | 0.040 |
Why?
| | Ions | 1 | 2018 | 67 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1310 | 0.030 |
Why?
| | Nitriles | 1 | 1999 | 176 | 0.030 |
Why?
| | Solutions | 2 | 2016 | 169 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1194 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2018 | 66 | 0.030 |
Why?
| | Nifedipine | 1 | 1997 | 28 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 410 | 0.030 |
Why?
| | Urea | 1 | 2018 | 79 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 1998 | 124 | 0.030 |
Why?
| | Bioreactors | 1 | 2018 | 48 | 0.030 |
Why?
| | Bronchi | 1 | 1999 | 267 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1998 | 104 | 0.030 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 429 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 538 | 0.030 |
Why?
| | Intestines | 1 | 2000 | 354 | 0.030 |
Why?
| | Food Hypersensitivity | 2 | 2011 | 182 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2011 | 197 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 185 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2017 | 72 | 0.030 |
Why?
| | Archaeal Proteins | 1 | 2017 | 45 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2159 | 0.030 |
Why?
| | Postoperative Care | 1 | 1999 | 265 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1058 | 0.030 |
Why?
| | Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1133 | 0.030 |
Why?
| | Schizophrenic Psychology | 1 | 2017 | 98 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 371 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2008 | 158 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 370 | 0.030 |
Why?
| | Temperature | 1 | 2000 | 673 | 0.030 |
Why?
| | Hydrolysis | 2 | 2013 | 194 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2017 | 60 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2925 | 0.030 |
Why?
| | Catheterization | 1 | 2017 | 177 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 191 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 31 | 0.030 |
Why?
| | Cell Count | 2 | 2013 | 318 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | Anterior Chamber | 1 | 1996 | 25 | 0.030 |
Why?
| | Anesthesia, Intravenous | 1 | 2016 | 16 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 668 | 0.030 |
Why?
| | Materials Testing | 1 | 2018 | 349 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 354 | 0.030 |
Why?
| | Bromocriptine | 1 | 1996 | 31 | 0.030 |
Why?
| | Nonlinear Dynamics | 1 | 2016 | 88 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2010 | 2562 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 1996 | 54 | 0.030 |
Why?
| | Duodenum | 1 | 1996 | 76 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 375 | 0.030 |
Why?
| | Nicotinic Agonists | 1 | 2017 | 132 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2422 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 580 | 0.030 |
Why?
| | Syringes | 1 | 2016 | 43 | 0.030 |
Why?
| | Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 476 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2007 | 1916 | 0.030 |
Why?
| | Health Policy | 1 | 1999 | 397 | 0.030 |
Why?
| | Incidence | 2 | 2018 | 2827 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 681 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 44 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 688 | 0.030 |
Why?
| | Neuroglia | 1 | 1996 | 171 | 0.030 |
Why?
| | Estradiol | 1 | 2019 | 525 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 409 | 0.030 |
Why?
| | Citric Acid Cycle | 2 | 2010 | 59 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 321 | 0.030 |
Why?
| | Safety | 1 | 2017 | 345 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 420 | 0.030 |
Why?
| | Rhodamines | 1 | 1995 | 20 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 1996 | 535 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1995 | 40 | 0.030 |
Why?
| | Heat-Shock Proteins | 2 | 2007 | 144 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 22 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 19 | 0.030 |
Why?
| | Oxides | 1 | 1995 | 47 | 0.030 |
Why?
| | Pain Measurement | 2 | 2010 | 527 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 255 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 407 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 384 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 1996 | 373 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 391 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1995 | 55 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 588 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 86 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Kidney Function Tests | 3 | 2006 | 158 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 92 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 912 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 452 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 125 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 12 | 0.030 |
Why?
| | Nevirapine | 1 | 2013 | 17 | 0.030 |
Why?
| | Benzoxazines | 1 | 2013 | 31 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2013 | 68 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 1999 | 86 | 0.030 |
Why?
| | Alkynes | 1 | 2013 | 57 | 0.030 |
Why?
| | Cognition Disorders | 1 | 2017 | 504 | 0.030 |
Why?
| | Phospholipases | 1 | 2013 | 14 | 0.030 |
Why?
| | Mannitol | 2 | 2006 | 38 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2013 | 25 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2374 | 0.030 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 483 | 0.030 |
Why?
| | Models, Molecular | 2 | 2013 | 1598 | 0.020 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 56 | 0.020 |
Why?
| | Laparoscopy | 1 | 2017 | 445 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 46 | 0.020 |
Why?
| | Heart Rate | 2 | 2009 | 800 | 0.020 |
Why?
| | Mothers | 1 | 2019 | 765 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 392 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 695 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 203 | 0.020 |
Why?
| | Leucovorin | 1 | 2012 | 84 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 98 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 73 | 0.020 |
Why?
| | Vascular System Injuries | 1 | 2013 | 73 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3664 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 7 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Asialoglycoprotein Receptor | 2 | 2006 | 7 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 151 | 0.020 |
Why?
| | Fear | 1 | 2015 | 342 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 199 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 26 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2007 | 738 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1076 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 193 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 32 | 0.020 |
Why?
| | Phenobarbital | 1 | 1991 | 17 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1616 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 1991 | 22 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 788 | 0.020 |
Why?
| | Actins | 2 | 2007 | 418 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 176 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 174 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 19 | 0.020 |
Why?
| | Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
| | Femoral Artery | 1 | 2013 | 184 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 195 | 0.020 |
Why?
| | Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 577 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 76 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 280 | 0.020 |
Why?
| | Contrast Media | 1 | 1995 | 470 | 0.020 |
Why?
| | Fluorouracil | 1 | 2012 | 201 | 0.020 |
Why?
| | Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 7 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 1991 | 29 | 0.020 |
Why?
| | Centrifugation | 1 | 1991 | 27 | 0.020 |
Why?
| | Immunoenzyme Techniques | 3 | 1996 | 208 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 190 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 574 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 373 | 0.020 |
Why?
| | Food Analysis | 1 | 2011 | 26 | 0.020 |
Why?
| | Alfentanil | 1 | 2010 | 3 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2586 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 109 | 0.020 |
Why?
| | Aldehydes | 1 | 1991 | 144 | 0.020 |
Why?
| | Pain Perception | 1 | 2010 | 24 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 621 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1052 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2838 | 0.020 |
Why?
| | Cell Division | 3 | 2001 | 790 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 199 | 0.020 |
Why?
| | Serologic Tests | 1 | 2010 | 53 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 888 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 883 | 0.020 |
Why?
| | Blood | 2 | 2000 | 110 | 0.020 |
Why?
| | Protein Conformation | 1 | 2013 | 944 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 157 | 0.020 |
Why?
| | Spinacia oleracea | 1 | 2009 | 9 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 96 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1011 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2010 | 137 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 180 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 86 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 362 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Insulin Lispro | 1 | 2009 | 39 | 0.020 |
Why?
| | Serbia | 1 | 2008 | 7 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2009 | 52 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2009 | 91 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 39 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 113 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 635 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 218 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 195 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 369 | 0.020 |
Why?
| | Urinalysis | 1 | 2009 | 77 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5731 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2008 | 35 | 0.020 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 40 | 0.020 |
Why?
| | Naloxone | 1 | 2009 | 121 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 331 | 0.020 |
Why?
| | Monocrotaline | 1 | 2007 | 35 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 14 | 0.020 |
Why?
| | HIV-1 | 1 | 2013 | 887 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1983 | 0.020 |
Why?
| | Fasting | 1 | 2009 | 284 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 844 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 343 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2007 | 48 | 0.020 |
Why?
| | Technetium | 1 | 2006 | 9 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 5 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 2006 | 13 | 0.020 |
Why?
| | Systole | 1 | 2007 | 183 | 0.020 |
Why?
| | Radiography | 2 | 2000 | 846 | 0.020 |
Why?
| | Cell Size | 2 | 1997 | 90 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1988 | 298 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 288 | 0.020 |
Why?
| | Dosage Forms | 2 | 1996 | 9 | 0.020 |
Why?
| | Serum Albumin, Human | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2006 | 38 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 4 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 23 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2006 | 115 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1260 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 43 | 0.020 |
Why?
| | Insulin, Regular, Human | 1 | 2006 | 43 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 61 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 151 | 0.020 |
Why?
| | Portal System | 1 | 2006 | 14 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 828 | 0.020 |
Why?
| | Insulin, Long-Acting | 1 | 2006 | 63 | 0.020 |
Why?
| | Cold Ischemia | 1 | 2006 | 30 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 362 | 0.020 |
Why?
| | Electroencephalography | 1 | 2009 | 434 | 0.020 |
Why?
| | Biopsy | 2 | 2000 | 1089 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 979 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 88 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2006 | 240 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2007 | 302 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2861 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2009 | 351 | 0.010 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2006 | 82 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 198 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 101 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2006 | 334 | 0.010 |
Why?
| | Escherichia coli | 1 | 2009 | 826 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1996 | 435 | 0.010 |
Why?
| | Travel | 1 | 2006 | 136 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 109 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 521 | 0.010 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 344 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1487 | 0.010 |
Why?
| | Motor Skills | 1 | 1985 | 100 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1049 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2166 | 0.010 |
Why?
| | Polymers | 1 | 2008 | 490 | 0.010 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 552 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2006 | 255 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 573 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 244 | 0.010 |
Why?
| | Absorption | 1 | 2003 | 60 | 0.010 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2762 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 503 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 2003 | 80 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 94 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 171 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2003 | 135 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1077 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 152 | 0.010 |
Why?
| | gamma-Glutamyltransferase | 2 | 1994 | 42 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 33 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 179 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1995 | 3608 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 195 | 0.010 |
Why?
| | Alkaline Phosphatase | 2 | 1994 | 151 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 5 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2001 | 28 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 148 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 378 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 32 | 0.010 |
Why?
| | Transfection | 1 | 2003 | 938 | 0.010 |
Why?
| | Calorimetry | 1 | 2001 | 71 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1791 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2001 | 148 | 0.010 |
Why?
| | Cell Membrane | 2 | 1995 | 713 | 0.010 |
Why?
| | Quantum Theory | 1 | 2001 | 92 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 245 | 0.010 |
Why?
| | Coloring Agents | 1 | 2000 | 87 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 66 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1802 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 95 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 338 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1991 | 51 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 987 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2006 | 793 | 0.010 |
Why?
| | Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
| | Crotonates | 1 | 1999 | 5 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2799 | 0.010 |
Why?
| | Toluidines | 1 | 1999 | 7 | 0.010 |
Why?
| | Remission Induction | 1 | 2000 | 291 | 0.010 |
Why?
| | Vinblastine | 1 | 1999 | 70 | 0.010 |
Why?
| | Capsules | 2 | 1990 | 39 | 0.010 |
Why?
| | Thermodynamics | 1 | 2001 | 423 | 0.010 |
Why?
| | Ultrasonography | 1 | 2003 | 774 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2004 | 709 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 348 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1999 | 109 | 0.010 |
Why?
| | Isoxazoles | 1 | 1999 | 53 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 424 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1999 | 102 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1999 | 523 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1999 | 169 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1317 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2000 | 447 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 662 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 229 | 0.010 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
| | Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
| | Azathioprine | 1 | 1996 | 49 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 987 | 0.010 |
Why?
| | Tissue Donors | 1 | 2000 | 416 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1477 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1996 | 91 | 0.010 |
Why?
| | Administration, Topical | 1 | 1996 | 145 | 0.010 |
Why?
| | Ophthalmic Solutions | 1 | 1996 | 77 | 0.010 |
Why?
| | Acetonitriles | 1 | 1995 | 12 | 0.010 |
Why?
| | Bile Canaliculi | 1 | 1995 | 4 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1709 | 0.010 |
Why?
| | Albumins | 1 | 1996 | 117 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1996 | 136 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 306 | 0.010 |
Why?
| | Fetuins | 1 | 1995 | 2 | 0.010 |
Why?
| | Cornea | 1 | 1996 | 148 | 0.010 |
Why?
| | Cataract Extraction | 1 | 1996 | 103 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 36 | 0.010 |
Why?
| | Ferrosoferric Oxide | 1 | 1995 | 24 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 1996 | 192 | 0.010 |
Why?
| | Skin | 1 | 1999 | 753 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 174 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1996 | 326 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1994 | 187 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1995 | 465 | 0.010 |
Why?
| | Vinca Alkaloids | 1 | 1993 | 6 | 0.010 |
Why?
| | Affinity Labels | 1 | 1993 | 24 | 0.010 |
Why?
| | Succinimides | 1 | 1993 | 19 | 0.010 |
Why?
| | Daunorubicin | 1 | 1993 | 24 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1711 | 0.010 |
Why?
| | Collagen | 1 | 1996 | 454 | 0.010 |
Why?
| | Bile Acids and Salts | 1 | 1994 | 154 | 0.010 |
Why?
| | Cricetulus | 1 | 1993 | 110 | 0.010 |
Why?
| | CHO Cells | 1 | 1993 | 167 | 0.010 |
Why?
| | Cricetinae | 1 | 1993 | 296 | 0.010 |
Why?
| | Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 145 | 0.010 |
Why?
| | Tritium | 1 | 1992 | 71 | 0.010 |
Why?
| | Water | 1 | 1995 | 468 | 0.010 |
Why?
| | Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
| | Cholinesterases | 1 | 1991 | 9 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 168 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1991 | 84 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1991 | 150 | 0.010 |
Why?
| | Oils | 1 | 1990 | 21 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1993 | 738 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1994 | 759 | 0.000 |
Why?
| | Antigen-Antibody Reactions | 1 | 1987 | 55 | 0.000 |
Why?
| | Gelatin | 1 | 1988 | 53 | 0.000 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 97 | 0.000 |
Why?
| | CD3 Complex | 1 | 1987 | 104 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1987 | 718 | 0.000 |
Why?
|
|
Christians's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|